^
BIOMARKER:

RET fusion

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Entrez ID:
RET fusion
NSCLC
KN046
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
RET fusion
NSCLC
HA121-28
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Follicular Carcinoma
selpercatinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: A2 - Guideline
RET fusion
NSCLC
vandetanib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Follicular Carcinoma
pralsetinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive: A2 - Guideline
RET fusion
Lung Cancer
lenvatinib
Sensitive: B - Late Trials
RET fusion
Pancreatic Cancer
pralsetinib
Sensitive: C1 - Off-label
RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive: C1 - Off-label
RET fusion
Breast Cancer
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Pancreatic Adenocarcinoma
pralsetinib
Sensitive: C1 - Off-label
RET fusion
Colon Cancer
pralsetinib
Sensitive: C1 - Off-label
RET fusion
Neuroendocrine Tumor
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Sarcoma
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Ovarian Cancer
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Small Intestinal Carcinoma
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Pancreatic Cancer
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Colon Cancer
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Salivary Gland Cancer
pralsetinib
Sensitive: C1 - Off-label
RET fusion
LUAD
pralsetinib
Sensitive: C1 - Off-label
RET fusion
NSCLC
durvalumab
Resistant: C2 – Inclusion Criteria
RET fusion
NSCLC
cabozantinib capsule
Sensitive: C3 – Early Trials
RET fusion
Thyroid Gland Papillary Carcinoma
cabozantinib tablet
Sensitive: C3 – Early Trials
RET fusion
NSCLC
everolimus + vandetanib
Sensitive: C3 – Early Trials
RET fusion
Pancreatic Cancer
BOS-172738
Sensitive: C3 – Early Trials
RET fusion
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
RET fusion
NSCLC
alectinib + abemaciclib
Sensitive: D – Preclinical
RET fusion
NSCLC
palbociclib + alectinib
Sensitive: D – Preclinical